Highlights
- CHM has gained the FDA approval for its IND application for CHM 2101.
- Patient enrolment for the Phase 1A clinical trial is expected to begin in 2024.
- The study will focus on gastrointestinal cancers.
Chimeric Therapeutics Limited (ASX: CHM) has reported another milestone, receiving approval from the US FDA for its Investigational New Drug (IND) application.
The latest development concerns CHM 2101, which is a third-generation CDH17 CAR T cell therapy targeting gastrointestinal cancers, including neuroendocrine tumours, gastric cancer and colorectal cancer.
With this development, the company can commence its Phase 1A/B clinical trial. Patient enrolment for the multi-centre, open label study is expected to start in 2024.
CHM share price jumps over 70%
CHM shares jumped 73.08% to trade at AU$0.045 apiece at the time of writing on 31 October 2023, with a market cap of AU$13.88 million.